Abstract
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3’,5’ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels of amyloid beta (Aβ) production (Tg2576). Objective: This Phase 2 multicenter study was designed to assess the efficacy, safety and pharmacokinetics of PF-04447943 compared with placebo in mild to moderate probable Alzheimer’s disease (AD). Methods: Subjects in overall good health with Mini Mental State Examination (MMSE) scores of 14-26 were randomized to 12 weeks treatment with PF-04447943 25 mg q12h (n=91) or placebo (n=100). Concomitant acetylcholinesterase inhibitor or memantine use was excluded. The primary outcome was the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog). The Neuropsychiatric Inventory (NPI), Clinical Global Impression-Improvement scale (CGI-I) and standard safety measures were secondary outcomes. Results: Completion rates were similar, 87% PF-04447943 vs 92% placebo. At week 12 the mean (SE) baseline adjusted decrease from baseline in ADAS cog for PF-04447943-treated patients was -1.91 (0.54). Placebo treated patients had a change of -1.60 (0.50). The difference between treatments was -0.31 (90% CI of -1.52, 0.90). Corresponding values for the NPI were -2.86 (0.72) vs -2.70 (0.67) with a treatment difference of -0.16 (90% CI of -1.78, 1.48). Neither these changes nor the distribution of CGI-I scores were statistically significantly different between groups. The incidence of serious adverse events (AEs) was similar between groups with 2 deaths in the placebo group. The PF-04447943 group reported more gastrointestinal AEs including diarrhea (5.5% vs 3%) and nausea (5.5% vs 1%) and had a higher rate of discontinuation due to AEs (6.6% vs 2%). Conclusions: Although generally safe and well-tolerated, 12 weeks PF-04447943 treatment did not improve cognition, behavior, and global change compared with placebo.
Keywords: Phosphodiesterase 9 inhibitor, Alzheimer's disease, PF-04447943.
Current Alzheimer Research
Title:A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Volume: 11 Issue: 5
Author(s): Elias M. Schwam, Timothy Nicholas, Robert Chew, Clare B. Billing, Wendy Davidson, Darlene Ambrose and Larry D. Altstiel
Affiliation:
Keywords: Phosphodiesterase 9 inhibitor, Alzheimer's disease, PF-04447943.
Abstract: Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3’,5’ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels of amyloid beta (Aβ) production (Tg2576). Objective: This Phase 2 multicenter study was designed to assess the efficacy, safety and pharmacokinetics of PF-04447943 compared with placebo in mild to moderate probable Alzheimer’s disease (AD). Methods: Subjects in overall good health with Mini Mental State Examination (MMSE) scores of 14-26 were randomized to 12 weeks treatment with PF-04447943 25 mg q12h (n=91) or placebo (n=100). Concomitant acetylcholinesterase inhibitor or memantine use was excluded. The primary outcome was the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog). The Neuropsychiatric Inventory (NPI), Clinical Global Impression-Improvement scale (CGI-I) and standard safety measures were secondary outcomes. Results: Completion rates were similar, 87% PF-04447943 vs 92% placebo. At week 12 the mean (SE) baseline adjusted decrease from baseline in ADAS cog for PF-04447943-treated patients was -1.91 (0.54). Placebo treated patients had a change of -1.60 (0.50). The difference between treatments was -0.31 (90% CI of -1.52, 0.90). Corresponding values for the NPI were -2.86 (0.72) vs -2.70 (0.67) with a treatment difference of -0.16 (90% CI of -1.78, 1.48). Neither these changes nor the distribution of CGI-I scores were statistically significantly different between groups. The incidence of serious adverse events (AEs) was similar between groups with 2 deaths in the placebo group. The PF-04447943 group reported more gastrointestinal AEs including diarrhea (5.5% vs 3%) and nausea (5.5% vs 1%) and had a higher rate of discontinuation due to AEs (6.6% vs 2%). Conclusions: Although generally safe and well-tolerated, 12 weeks PF-04447943 treatment did not improve cognition, behavior, and global change compared with placebo.
Export Options
About this article
Cite this article as:
Schwam M. Elias, Nicholas Timothy, Chew Robert, Billing B. Clare, Davidson Wendy, Ambrose Darlene and Altstiel D. Larry, A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease, Current Alzheimer Research 2014; 11 (5) . https://dx.doi.org/10.2174/1567205011666140505100858
DOI https://dx.doi.org/10.2174/1567205011666140505100858 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure in South America
Current Cardiology Reviews The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Increased Production of Nitric Oxide Mediates Selective Organ-Specific Effects of Endotoxin on Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
Combinatorial Chemistry & High Throughput Screening Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Safe and Effective Delivery of Amphotericin B: A Survey of Patents
Recent Patents on Nanotechnology